The Female Health Company Declares 1st Quarter Dividend of $0.05/Share
CHICAGO, Jan. 14, 2011 /PRNewswire via COMTEX/ -- The Female Health Company
(FHCO), today announced that its Board of Directors has declared a quarterly cash
dividend of $0.05 per share. The dividend is payable February 7, 2011 to
stockholders of record as of January 31, 2011.
In January, 2010, the Company announced the initiation of a cash dividend program
and paid dividends in February, May, August and November 2010.
"The Company's Board of Directors and management team believe that the payment of
cash dividends allows shareholders to participate directly in the Company's
success," stated O.B. Parrish, Chairman and Chief Executive Officer of The Female
Health Company. "The Company's profitability has generated cash from operations
that exceeds the Company's capital spending requirements; and the Company is debt
free. We believe that utilizing some of this excess cash flow to pay cash
dividends is in the best interests of our shareholders."
Any future quarterly dividends and the record date for any such dividend will be
approved each quarter by the Company's Board of Directors and announced by the
Company. Payment of future dividends is in the discretion of the Board of
Directors and the Company may not have sufficient cash flows to continue to pay
dividends.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets
the FC2 Female Condom(R) (FC2), which is available in the U.S. and about 100
other countries around the world. The Company owns certain worldwide rights to
the FC2 Female Condom(R), including patents that have been issued in the U.S.,
Europe, Canada, Australia, South Africa, Japan, China, Spain, Mexico, Greece and
Turkey and are pending in various countries. The FC2 Female Condom(R) is the only
available FDA-approved product controlled by a woman that offers dual protection
against sexually transmitted diseases, including HIV/AIDS, and unintended
pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by
U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this release which are not historical fact are "forward-looking
statements" as that term is defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this release relate to the
continuation of cash dividends in future periods. These statements are based upon
the Company's current plans and strategies, and reflect the Company's current
assessment of the risks and uncertainties related to its business, and are made
as of the date of this release. The Company assumes no obligation to update any
forward-looking statements contained in this release as a result of new
information or future events, developments or circumstances. Such forward-looking
statements are inherently subject to known and unknown risks and uncertainties.
The Company's actual results and future developments could differ materially from
the results or developments expressed in, or implied by, these forward-looking
statements. Factors that may cause actual results to differ materially from those
contemplated by such forward-looking statements include, but are not limited to,
the following: product demand and market acceptance; competition in the Company's
markets and the risk of new competitors and new competitive product
introductions; the Company's reliance on its international partners in the
consumer sector and on the level of spending on the female condom by country
governments, global donors and other public health organizations in the global
public sector; the economic and business environment and the impact of government
pressures; risks involved in doing business on an international level, including
currency risks, regulatory requirements, political risks, export restrictions and
other trade barriers; the Company's production capacity, efficiency and supply
constraints; and other risks detailed in the Company's press releases,
shareholder communications and Securities and Exchange Commission filings,
including the Company's Form 10-K for the fiscal year ended September 30, 2010.
Actual events affecting the Company and the impact of such events on the
Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's website
at femalehealth.com and femalecondom.org. If you would like
to be added to the Company's e-mail alert list, please send an e-mail to
FHCInvestor@femalehealthcompany.com. |
